Key Points {#FPar1}
==========

There is a shift toward the use of oral prostacyclins in treating pulmonary arterial hypertension (PAH) given the improved convenience of this administration route relative to parenteral and inhaled therapy.Real-world claims data show relatively similar utilization patterns, with lower all-cause and PAH-related total healthcare and pharmacy costs observed in patients receiving oral treprostinil compared with selexipag.

Introduction {#Sec1}
============

Pulmonary arterial hypertension (PAH) is a chronic disease characterized by increased pulmonary vascular resistance and progressive right ventricular dysfunction \[[@CR1]\]. Survival in patients with PAH is poor but has improved considerably in the era since the US FDA's approval of therapies indicated for PAH \[[@CR2]\]. The 5-year survival in patients with PAH ranges from 59 to 68% \[[@CR3]--[@CR5]\]. Various risk score calculators have been developed for predicting contemporary survival \[[@CR6]--[@CR9]\], and certain indicators, including B-type natriuretic peptide, N-terminal pro B-type natriuretic peptide, functional status, and 6-minute walk distance, are predictors of outcomes and survival \[[@CR5], [@CR10], [@CR11]\].

Treatment guidelines have historically recommended initial monotherapy determined by baseline severity of World Health Organization (WHO) functional class (FC) with PAH-approved therapies from four medication classes, including endothelin receptor agonists (ERA), phosphodiesterase-5 inhibitors (PDE-5i), prostacyclin-class therapies, and soluble guanylate cyclase (SGC) stimulators, followed by sequential combination therapy for patients in whom response is inadequate \[[@CR12]\]. Following results from the AMBITION trial and other research showing a lower risk of clinical failure events and improved survival in patients with upfront combination therapy \[[@CR13], [@CR14]\], clinical practice guidelines have increasingly recommended initial combination drug therapy \[[@CR1], [@CR15]\].

Prostacyclins are a member of the eicosanoid family of lipids produced from arachidonic acid in a multistep process. The binding of prostacyclin to platelets and endothelial cells results in the inhibition of platelet aggregation, relaxation of smooth muscle, and pulmonary artery dilation, which mediates the vasoconstriction associated with PAH and improves cardiac output \[[@CR16]\]. Prostacyclin-class therapies are most often used in combination therapy in either first- or second-line regimens in patients with advanced FC \[[@CR1], [@CR17]\] and are prescribed to about one-quarter of patients \[[@CR17]--[@CR19]\]. More recently, there has been a shift from parenteral to nonparenteral prostacyclin use \[[@CR19]\]. Treprostinil extended-release tablets and selexipag are two oral therapies that target the prostacyclin pathway and are approved for the treatment of PAH. Since the FDA approval of oral treprostinil in 2013 and selexipag in 2015, which have improved convenience and safety compared with parenteral prostanoids, use of oral prostacyclin therapies has increased and is likely to continue \[[@CR17], [@CR19]\].

The goal of treatment is to reduce the progression of symptoms, improve FC \[[@CR20], [@CR21]\], and lower mortality risk among patients with PAH \[[@CR6]--[@CR9]\]. Recent studies have shown that oral prostacyclin therapies may be effective at delaying disease progression and reducing the risk of mortality \[[@CR22], [@CR23]\]. Results of the FREEDOM-EV study of oral treprostinil in patients with PDE-5i/SGC stimulator or ERA background monotherapy reported a clinically and statistically significant reduction in clinical worsening, defined as death from any cause, hospitalization for worsening PAH, disease progression, initiation of inhaled or infused prostacyclin therapy, or unsatisfactory long-term clinical response \[[@CR24]\]. Similarly, the GRIPHON study of selexipag in patients with either no background therapy, a PDE-5i, and/or an ERA demonstrated a reduction in clinical worsening, defined as death from any cause or a PAH-related complication, including disease progression or worsening that resulted in hospitalization, initiation of parenteral prostanoid therapy or long-term oxygen therapy, or the need for lung transplantation or balloon atrial septostomy \[[@CR21]\].

While the safety and efficacy of oral prostacyclin therapies is well-established, little is known about their impact on the utilization and costs of PAH-related care in the real-world setting, as reduced costs can reflect an important benefit of treatment. This study identified patients initiating oral treprostinil versus selexipag using claims data and evaluated real-world differences in patient characteristics, medication adherence, persistence, healthcare resource use (HCRU), and costs.

Methods {#Sec2}
=======

Study Design and Data Source {#Sec3}
----------------------------

This retrospective cohort study used integrated healthcare claims data from the IBM^®^ MarketScan databases (MarketScan), including the Commercial Claims Encounters Database and Medicare Supplemental Database during the study period from 1 July 2013 to 30 September 2017 (Fig. [1](#Fig1){ref-type="fig"}). Adults with PAH aged ≥ 18 years were identified using a recommended algorithm for identifying patients with PAH from claims data, which required a diagnosis code for pulmonary hypertension (PH) plus a prescription for oral treprostinil or selexipag \[[@CR25]\]. PH diagnosis was identified by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and ICD-10-CM diagnostic codes (ICD-9-CM: 416.0, 416.8, 416.9; ICD-10-CM: I27.0, I27.2, I27.81, I27.89, I27.9). Oral prostacyclin therapies were identified using national drug codes available within the pharmacy claims. The index date was the date of the first prescription for oral prostacyclin therapy during the identification period from 1 January 2014 to 31 March 2017.Fig. 1Study design. The index date is defined as first pharmacy claim for oral treprostinil or selexipag. *HCRU* healthcare resource use, *PAH* pulmonary arterial hypertension

Patients were required to have had continuous enrollment in the health plan during the 6-month pre-index and post-index periods, a PH diagnosis code during the 6-month pre-index period, and no pharmacy claims for oral treprostinil or selexipag during the pre-index period. Baseline demographic and clinical characteristics and utilization were assessed in the 6-month pre-index period, and HCRU, costs, and treatment patterns, including adherence, persistence, and dosing, were assessed during the 6-month post-index period. Healthcare Common Procedure Coding System codes were used for identifying medical claims for parenteral prostacyclin-class therapies.

Study Outcomes {#Sec4}
--------------

Treatment adherence was measured using the medication possession ratio (MPR) and the proportion of days covered (PDC). The MPR numerator was defined as the sum of the days of supply for the index regimen medication fills during the 6-month follow-up, and the denominator was the number of days between the first and last fill plus days of supply of the last fill. MPR was reported as a mean percentage ranging from 0 to 1. MPR was also reported as the proportion of patients with at least 80% mean MPR. The PDC numerator was defined as the sum of the days of supply for the index regimen medication fills during the 6-month follow-up, and the denominator was the total number of days in the 6-month follow-up. PDC was reported as a mean percentage ranging from 0 to 1 and also reported as the proportion of patients with at least 80% PDC. Treatment persistence was measured as the proportion of patients who did not have a gap of a defined duration of 60 days in the index therapy regimen during the 6-month follow-up. Time to treatment discontinuation was defined as the number of days of index therapy regimen from the index date to start of the first gap of a defined duration of ≥ 60 days. A sensitivity analysis was used to assess treatment persistence and time to treatment using a gap of defined duration of ≥ 30 days.

All-cause and PAH-related HCRU during the baseline and follow-up periods are reported. All-cause HCRU during follow-up was computed by the setting of care identified from the claims data using the place of service variable and applicable Current Procedural Terminology, 4th edition procedure codes. HCRU is reported for medical utilization, broken down by inpatient and outpatient visits, and for pharmacy utilization. Medical utilization was defined as the average number of unique visits per patient by type of visit. Pharmacy utilization was defined as the number of unique prescriptions filled per patient. PAH-related HCRU was identified using PH diagnosis codes in any position.

All-cause and PAH-related healthcare costs during the follow-up period are reported. Costs reflect all payments made to providers of care from both the health plan (plan and coordination of benefits) and the patient (copayment, coinsurance, deductible). All costs were adjusted to \$US, year 2017 values, using the Bureau of Labor Statistics medical care component of the Consumer Price Index.

Statistical Analysis {#Sec5}
--------------------

Descriptive statistics (percentages, means, medians, standard deviations \[SDs\]) were used to describe baseline demographic/clinical characteristics, adherence and persistence, and dosing for the oral treprostinil and selexipag cohorts. Chi-squared tests or Fischer's exact test were used for comparisons of frequencies between the cohorts, and Wilcoxon--Mann--Whitney tests were used for continuous variables.

Mean doses of oral prostacyclin therapies were calculated for each month of follow-up for patients in each treatment group who were prostacyclin naïve in the 6 months prior to index treatment. For patients receiving selexipag, dosing was calculated following the first claim for a nonstarter pack. Mean doses were evaluated separately in the subset of patients who used a prostacyclin via an alternative administration route prior to oral therapy, as patients transitioning to oral prostacyclin therapies from an alternative route initiate oral treatment at higher daily doses comparable to their daily doses for nonparenteral prostacyclin. A sensitivity analysis was also conducted to explore mean daily doses of oral prostacyclin therapies over a longer 12-month period among the subset of patients persistent on oral prostacyclin therapies for 12 months.

Unadjusted HCRU and costs are reported overall and for PAH-related visits as the number and percentage for categorical measures and as means ± SDs for continuous measures. Adjusted all-cause and PAH-related costs were estimated using recycled predictions and bootstrapped samples \[[@CR26]--[@CR28]\]. Costs during post-index follow-up were adjusted for baseline characteristics, including age, sex, region, and insurance plan type; prior prostacyclin use; presence of comorbid conditions; receipt of right heart catheterization (RHC); and pharmacy, inpatient, and total outpatient costs. Pharmacy costs for oral prostacyclin therapies were also explored in sensitivity analyses among the subset of patients persistent on oral prostacyclin-class therapies for 6 and 12 months. All analyses were conducted using SAS version 9.4 (SAS Institute, Inc; Cary, NC, USA).

Results {#Sec6}
=======

A total of 405 patients initiated oral treprostinil or selexipag during the study period. After applying study criteria, 256 patients with PAH (130 receiving oral treprostinil; 126 receiving selexipag) met the study criteria. Table [1](#Tab1){ref-type="table"} provides a description of the baseline demographic and clinical characteristics of the study cohort. Oral treprostinil and selexipag patients were of similar age (mean 58.0 ± 16.2 vs. 58.5 ± 13.0 years for oral treprostinil and selexipag, respectively) and had a similar Charlson Comorbidity Index (mean 3.5 ± 2.6 vs. 3.2 ± 2.2 for oral treprostinil and selexipag, respectively). The proportion of males was higher in the oral treprostinil cohort (33.1 vs. 16.7% for oral treprostinil and selexipag, respectively; *p *\< 0.01). Rates of specific comorbidities varied, with more rheumatic disease in the selexipag cohort (20 vs. 32.5% for oral treprostinil and selexipag, respectively; *p *= 0.023) and a nonsignificant trend toward more renal disease and AIDS/HIV in the oral treprostinil cohort. There was a 10% difference in the proportion of patients who underwent RHC in the 6 months prior to being prescribed oral prostacyclin, although this difference did not meet statistical significance (47.7 vs. 36.5% for oral treprostinil and selexipag, respectively; *p *= 0.07).Table 1Baseline demographic, clinical characteristics, treatments, and costsCharacteristics, treatments, and costsOral treprostinil (*N* = 130)Selexipag (*N* = 126)*p* valueDemographic characteristics Age, years58.0 ± 16.258.5 ± 13.00.755 Males43 (33.1)21 (16.7)0.002 Geographic region0.106  Northeast31 (23.9)16 (12.7)  North Central31 (23.9)30 (23.8)  South54 (41.5)60 (47.6)  West14 (10.8)20 (15.9) Payer type0.139  Commercial86 (66.2)94 (74.6)  Medicare supplemental44 (33.9)32 (25.4)Clinical characteristics CCI, mean (SD)3.5 ± 2.63.2 ± 2.20.485 CCI comorbidities  Myocardial infarction5 (3.9)1 (0.8)0.214  Congestive heart failure64 (49.2)54 (42.9)0.306  Peripheral vascular disease18 (13.9)19 (15.1)0.779  Cerebrovascular disease9 (6.9)5 (4.0)0.412  Dementia0 (1.0)2 (3.0)--  Chronic pulmonary disease127 (97.7)126 (100.0)0.247  Rheumatic disease26 (20.0)41 (32.5)0.023  Peptic ulcer disease0 (0.0)1 (0.8)0.492  Mild liver disease8 (6.2)5 (4.0)0.572  Diabetes without chronic complication32 (24.6)32 (25.4)0.885  Diabetes with chronic complication17 (13.1)26 (20.6)0.106  Hemiplegia/paraplegia0 (1.0)2 (3.0)--  Renal disease29 (22.3)17 (13.5)0.066  Malignancy (any)11 (8.5)7 (5.6)0.363  Moderate or severe liver disease4 (3.1)5 (4.0)0.746  AIDS/HIV5 (3.9)0 (0.0)0.060 Right heart catheterization62 (47.7)46 (36.5)0.070 Echocardiography88 (67.7)85 (67.5)0.968Baseline PAH treatment classes ERAs94 (72.3)96 (76.2)0.478 PDE-5is86 (66.2)93 (73.8)0.182 sGC stimulator15 (11.5)16 (12.7)0.776 ERA + PDE-5i combination therapy57 (43.9)65 (51.6)0.215 ERA + sGC combination therapy9 (6.9)11 (8.7)0.590 Intravenous treprostinil17 (13.1)3 (2.4)0.002 Inhaled treprostinil23 (17.7)24 (19.1)0.779 Epoprostenol3 (2.3)2 (1.6)1.000 Iloprost5 (3.9)5 (4.0)1.000 Any parenteral prostacyclin (intravenous treprostinil, epoprostenol)19 (14.6)5 (4.0)0.004Healthcare costs Total healthcare cost\$105,249 ± 113,376\$93,619 ± 95,3090.360 Medical cost\$34,096 ± 100,989\$18,288 ± 25,3840.054  Inpatient cost\$10,212 ± 37,226\$6688 ± 18,0380.389  Total outpatient cost\$23,883 ± 88,718 \$11,600 ± 17,4500.025 Prescription costs\$71,153 ± 59,347\$75,331 ± 95,6470.999Data are presented as mean ± SD or N (%) unless otherwise indicated. Costs are presented as \$US, year 2017 values*AIDS* acquired immunodeficiency syndrome, *CCI* Charlson comorbidity index, *ERA* endothelin receptor antagonist, *HIV* human immunodeficiency virus, *PAH* pulmonary arterial hypertension, *PDE*-*5i* phosphodiesterase type-5 inhibitor, *SD* standard deviation, *sGC* soluble guanylate cyclase

Baseline treatment patterns were compared between the cohorts (Table [1](#Tab1){ref-type="table"}). A higher proportion of patients in the selexipag cohort used a PDE-5i alone or in combination with an ERA (73.8 vs. 66.2% for selexipag and oral treprostinil, respectively; *p *= 0.18) during baseline, although this difference was not statistically significant. More patients receiving oral treprostinil transitioned from a parenteral prostacyclin (14.6 vs. 4.0% for oral treprostinil and selexipag, respectively; *p *= 0.004).

Baseline total all-cause costs were similar between the cohorts except for all-cause outpatient costs, which were higher in the oral treprostinil cohort than in the selexipag cohort (mean \$23,883 ± 88,718 and \$11,600 ± 17,450, respectively; *p *= 0.025) (Table [1](#Tab1){ref-type="table"}). Mean baseline PAH-related medical and pharmacy costs were similar across the cohorts, as were PAH-related total healthcare costs.

Adherence and Persistence {#Sec7}
-------------------------

Following the initiation of oral prostacyclin therapy, the mean MPR was higher for oral treprostinil than for selexipag (0.89 ± 0.19 vs. 0.85 ± 0.22, respectively; *p *= 0.039). While the proportion of patients with MPR ≥ 80 was higher in the oral treprostinil cohort (82%) than in the selexipag cohort (77%), this difference was not statistically significant (Fig. [2](#Fig2){ref-type="fig"}). Mean PDC was similar between the cohorts (0.72 ± 0.31 vs. 0.71 ± 0.31 for oral treprostinil and selexipag, respectively; *p *= 0.483), and the proportion of patients with PDC ≥ 80 was the same in both cohorts (56%; *p *= 0.975). There was no significant difference between the cohorts in the proportion of patients persistent on therapy when discontinuation was defined as a gap of ≥ 60 days (71 vs. 72% for oral treprostinil and selexipag, respectively; *p *= 0.797) or a gap of ≥ 30 days (62 vs. 63%, respectively; *p *= 0.797).Fig. 2Medication adherence and persistence. *MPR* medication possession ratio, *PDC* proportion of days covered. \**p* \< 0.05

Prescriptions and Monthly Dosing {#Sec8}
--------------------------------

The mean number of prescriptions was 6.1 ± 3.3 and 5.8 ± 2.7 for oral treprostinil and selexipag, respectively, which did not differ between cohorts (*p *= 0.310). Similarly, the median and interquartile range (IQR) for the number of prescriptions was 6.5 (4--7) and 6 (5--7) for oral treprostinil and selexipag, respectively.

In prostacyclin-naïve patients, the median total daily dose at 6 months was 6.9 mg (IQR 2.2--9.5) for oral treprostinil and 2213 μg (IQR 1200--3093) for selexipag. Median total daily dose generally increased from month 1 through 6. In sensitivity analysis over 12 months post-index, daily median doses generally reached their highest point in month 6 and did not fluctuate much from 6 through 12 months.

In patients who received parenteral prostacyclin before initiation of oral prostacyclin, median total daily doses started higher, as expected, but also remained higher over 6-month follow-up than in those who were prostacyclin naïve. Among patients who received prior parenteral prostacyclin-class therapies, the median total daily dose at 6 months was 11.8 mg (IQR 4.4--20.4) for oral treprostinil and 2600 μg (IQR 1365--3200) for selexipag. In a sensitivity analysis over the 12-month post-index period among these patients, median total daily doses reached their highest points between months 6 and 12 for both cohorts, generally later than for those who were prostacyclin naïve at the time of oral prostacyclin initiation.

Healthcare Resource Use and Costs {#Sec9}
---------------------------------

There was no significant difference between the cohorts in all-cause inpatient visits (Table [2](#Tab2){ref-type="table"}) during the post-index period. The adjusted mean number of inpatient visits was 1.3 ± 0.6 for the oral treprostinil cohort and 1.9 ± 0.8 for the selexipag cohort (*p *= 0.199). Adjusted mean length of hospital stay was 8.6 ± 6.1 days for the oral treprostinil cohort and 10.4 ± 7.3 days for the selexipag cohort (*p *= 0.441). Similarly, the mean number of all-cause emergency department (ED) visits was similar (0.4 ± 1.1 and 0.4 ± 1.0 for oral treprostinil and selexipag, respectively; *p *= 0.917). However, the mean all-cause adjusted outpatient visits was higher in the oral treprostinil cohort (22.0 ± 8.4 vs. 18.8 ± 7.2 for oral treprostinil and selexipag, respectively; *p *\< 0.001).Table 2Healthcare resource utilization during the post-index periodHealthcare resource utilizationOral treprostinilSelexipag*p* value(*N* = 130)(*N* = 126)All-cause healthcare resource utilization Inpatient visits43 (33.1)29 (23.0) Inpatient visits^a^0.4 ± 0.70.4 ± 0.90.127 Adjusted inpatient visits^b^1.3 ± 0.61.9 ± 0.80.199 Length of stay per hospitalization5.8 ± 7.37.1 ± 7.40.297 Adjusted length of stay^b^8.6 ± 6.110.4 ± 7.30.441 Bed days^a^2.5 ± 6.42.8 ± 7.30.156Outpatient visits ED visits33 (25.4)32 (25.4)0.998 ED visits^a^0.4 ± 1.10.4 ± 1.00.917 Overall outpatient visits130 (100.0)126 (100.0)-- Overall outpatient visits^a^22.1 ± 16.618.7 ± 10.00.258 Adjusted overall outpatient visits^b^22.0 ± 8.418.8 ± 7.2\< 0.0001Unique prescriptions45 ± 2049 ± 220.121PAH-related healthcare resource utilization Inpatient visits10 (7.7)5 (4.0)0.205 Inpatient visits^a^0.1 ± 0.30.1 ± 0.30.211 Adjusted inpatient visits^b^1.2 ± 0.61.2 ± 0.61.000 Length of stay per hospitalization4.0 ± 2.35.0 ± 6.30.673 Adjusted length of stay^b^1.2 ± 0.41.3 ± 0.40.397 Bed days^a^0.3 ± 1.40.3 ± 2.00.201Outpatient visits ED visits3 (2.3)0 (0.0)0.086 ED visits^a^0.04 ± 0.30.0 ± 0.00.088 Overall outpatient visits125 (96.2)119 (94.4)0.518 Overall outpatient visits^a^5.8 ± 4.85.4 ± 4.80.280 Adjusted overall outpatient visits^b^5.8 ± 2.176.0 ± 2.210.748PAH-specific unique prescriptions13.9 ± 6.414 ± 5.90.658Data are presented as mean ± SD or *N* (%) unless otherwise indicated*ED* emergency department, *PAH* pulmonary arterial hypertension, *SD* standard deviation^a^Mean ± SD were calculated for the entire cohort^b^Adjusted for baseline age, sex, region, insurance plan type, prior prostacyclin use, presence of comorbid conditions, receipt of RHC and respective baseline pharmacy, inpatient, and total outpatient costs

There was no significant difference between the two cohorts for PAH-related medical utilization (inpatient visits, ED visits, and outpatient visits) or the number of unique PAH-related prescriptions (Table [2](#Tab2){ref-type="table"}). The mean number of all-cause unique prescriptions was similar between the cohorts (45 ± 20 vs. 49 ± 22 for oral treprostinil and selexipag, respectively; *p *= 0.121). Notably, a higher proportion of patients in the oral treprostinil cohort received RHC during the post-index period compared with the selexipag cohort (13.2 vs. 5.6%, respectively; *p *= 0.039).

All-cause healthcare costs differed between the cohorts (Fig. [3](#Fig3){ref-type="fig"}). The mean all-cause total pharmacy cost during the follow-up was higher in the cohort treated with selexipag (\$171,169 ± 111,812) than in the cohort treated with oral treprostinil (\$118,962 ± 110,675; *p *\< 0.001), and this largely contributed to the difference in total costs (\$189,375 ± 114,549) compared with the cohort treated with oral treprostinil (\$153,457 ± 159,761; *p *\< 0.001). Similar results were seen when comparing PAH-related total healthcare and pharmacy costs.Fig. 3Unadjusted all-cause and PAH-related healthcare costs. \**P *\< 0.001, ^†^*P *\< 0.05, ^‡^ \$US, year 2017 values. *PAH* pulmonary arterial hypertension

A sensitivity analysis was also conducted to explore pharmacy differences among persistent users throughout 6 and 12 months of follow-up (Table [3](#Tab3){ref-type="table"}). Analysis conducted over 6 and 12 months showed that higher pharmacy costs persisted in the selexipag cohort compared with the oral treprostinil cohort. At 6 months, the median pharmacy costs directly attributable to oral treprostinil (\$39,392 \[IQR 21,483--77,748\]) were significantly less than for selexipag (\$127,335 \[IQR 109,908--136,030\]; *p *\< 0.0001). Similarly, median pharmacy costs for persistent users over 12 months directly attributable to oral treprostinil (\$125,420 \[IQR 60,043--194,605\]) were significantly less than for selexipag (\$219,250 \[IQR 201,624--239,696\]; *p *\< 0.0001).Table 3Cost of oral treprostinil vs. selexipag among patients persistent on therapyOral prostacyclin costsOral treprostinilSelexipag*p* valuePatients persistent for 6 months*N* = 92*N* = 91 Mean ± SD69,745 ± 106,688136,494 ± 81,582 Median (IQR)39,392 (21,483--77,748)127,335 (109,908--136,030)\< 0.0001Patients persistent for 12 months*N* = 52*N* = 47 Mean ± SD189,222 ± 258,543230,852 ± 102,717 Median (IQR)125,420 (60,043--194,605)219,250 (201,624--239,696)\< 0.0001Costs are presented as \$US, year 2017 values*IQR* interquartile range, *SD* standard deviation

After adjustment for covariates, treatment with oral treprostinil was associated with 51.4% lower total all-cause healthcare costs than treatment with selexipag (difference in mean − \$73,680; 95% confidence interval \[CI\] − 103,702 to − 43,963) (Fig. [4](#Fig4){ref-type="fig"}). This difference in all-cause healthcare costs was largely driven by all-cause pharmacy costs, which were 68.2% lower in patients being treated with oral treprostinil than in those being treated with selexipag (difference in mean − \$77,654; 95% CI − 105,392 to − 52,118). Treatment with oral treprostinil was associated with 66.9% lower total PAH-related healthcare costs compared with being treated with selexipag (difference in mean − \$75,183; 95% CI − 102,584 to − 49,771). Differences in PAH-related healthcare costs were largely driven by PAH-related pharmacy costs, which were 70.62% lower in patients treated with oral treprostinil than in those treated with selexipag (difference in mean − \$76,439; 95% CI − 104,512 to − 51,458).Fig. 4Adjusted all-cause and PAH-related healthcare costs. \**P *\< 0.05. ^†^Adjusted for baseline age, sex, region, insurance plan type, prior prostacyclin use, presence of comorbid conditions, and receipt of RHC and baseline pharmacy, inpatient, and total outpatient costs. ^‡^\$US, year 2017 values. *PAH* pulmonary arterial hypertension, *RHC* right heart catheterization

Discussion {#Sec10}
==========

This is the first claims database study to compare treatment patterns and outcomes for patients with PAH initiating therapy with oral treprostinil versus selexipag. Results from this real-world study suggest there were no significant differences in all-cause and PAH-related medical HCRU between patients with PAH initiating therapy with oral treprostinil or selexipag during follow-up, except for all-cause outpatient visits, but there were significant differences in pharmacy utilization. Results suggest that treatment with oral treprostinil was associated with 51.4% lower total all-cause healthcare costs compared with treatment with selexipag, and this was largely driven by all-cause pharmacy costs, which were 68.2% lower in patients treated with oral treprostinil than in those treated with selexipag. Treatment with oral treprostinil was associated with 66.9% lower total PAH-related healthcare costs compared with treatment with selexipag, again largely driven by 70.6% lower PAH-related pharmacy costs in patients being treated with oral treprostinil than in those being treated with selexipag.

Medical care utilization was similar between the study cohorts receiving oral prostacyclin therapies. Notably, both cohorts reported similar hospitalization rates in both unadjusted and adjusted analyses. All-cause inpatient visits were comparable to those reported by Burger et al. \[[@CR19]\], in which the mean number of inpatient visits in the 6 months following the initiation of nonparenteral prostacyclin therapies was also 0.4. However, mean PAH-related inpatient visits were lower in our study cohorts (0.1 for both oral treprostinil and selexipag cohorts) than the 0.3 reported by Burger et al. \[[@CR19]\]. While the all-cause physician office visits were higher in the oral treprostinil cohort, PAH-related visits were similar between the oral prostacyclin cohorts. More physician office visits could be attributed to a higher proportion of patients in the oral treprostinil cohort receiving prior parenteral prostacyclin, which requires more frequent medical visits and may reflect a more advanced PAH disease stage. However, measures of PAH disease severity, such as FC and 6-minute walk distance, which may be useful for adjusting baseline differences, are not available within claims data. In the 6 months following oral prostacyclin initiation, a greater proportion of the oral treprostinil cohort received RHC. Taken together, these suggest that patients in the oral treprostinil cohort may have been sicker and hence more closely managed by their providers. However, it is important to point out that PAH-related medical costs decreased in both cohorts following the initiation of oral prostacyclin, and this reflects an important benefit of successful treatment. Our study shows that most of the healthcare cost was composed of pharmacy costs in both cohorts. This observation is similar to that in the study by Burger et al. \[[@CR19]\], who reported that mean all-cause pharmacy costs in patients treated with nonparenteral prostacyclins therapies for 6 months were \$96,539 ± 49,770, representing about 75% of the mean total all-cause healthcare costs of \$128,427 ± 120,938.

These real-world data also suggest that medication adherence and persistence with oral prostacyclin therapies were similar in the cohorts. MPR to oral prostacyclin was high in both the oral treprostinil (89%) and selexipag (85%) cohorts, similar to that reported by Burger et al. (89%) for prostacyclin use \[[@CR18]\]. However, PDC from this study (72 and 71% for oral treprostinil and selexipag, respectively) were lower than those reported by Studer et al. \[[@CR17]\] when prostacyclin therapies were initiated as part of combination therapy (90%), but the estimates from this study were higher than when prostacyclin therapies were initiated as monotherapy (50%).

Median total daily dosing for both oral prostacyclin-class therapies increased during the 6-month follow-up but generally remained at the same level through 12 months in patients with persistent use, suggesting that dosing titration usually takes up to 6 months following initiation of oral prostacyclin therapies. However, in patients transitioning from parenteral to oral prostacyclin, median total daily doses at initiation and throughout 12 months were higher than in prostacyclin-naïve patients. Those transitioning reached their highest levels between 6 and 12 months, peaking higher than in prostacyclin-naïve patients. This finding may reflect differences in patient severity, oral prostacyclin tolerance, or medical management. It should be noted that prior prostacyclin use at baseline was, therefore, controlled for in the analysis of HCRU and costs. Importantly, the transition from parenteral therapy was more common in those receiving oral treprostinil, and---after controlling for this---they still had lower healthcare costs than those in the selexipag cohort.

The difference in cost for oral prostacyclins cannot be directly attributable to variations in the wholesale acquisition cost of the respective drugs. The pricing models for oral treprostinil and selexipag are not directly comparable, as oral treprostinil is based on a price-per-dose model, with increased pricing for higher-dosage tablets, whereas selexipag is based on a fixed price that does not vary by dose. While fixed pricing, regardless of dosage, is often perceived as less costly and predictable \[[@CR29]\], dose-based pricing can result in lower costs with dose reductions \[[@CR30]\]. This study showed that, for oral prostacyclin drugs used in patients with PAH, treprostinil dose-based pricing led to lower pharmacy costs than the fixed pricing associated with selexipag.

Given that all HCRU, except for the number of outpatient visits, were similar between the cohorts during the post-index period and relatively similar at baseline, the higher overall healthcare cost can be attributed to treatment with selexipag. In patients receiving oral treprostinil, the medical cost was slightly higher; however, the difference was not statistically significant and may merely reflect a sicker baseline cohort given that patients receiving oral treprostinil had more often used parenteral therapy and had higher medical costs during baseline than those receiving selexipag. The reduction in medical costs following initiation of therapy in comparison to baseline medical costs reflects an important benefit of oral prostacyclins. Moreover, the slightly higher medical cost in the follow-up period was compensated by the lower overall pharmacy cost among patients receiving oral treprostinil and a larger decrease in medical costs relative to selexipag. This study provides real-world evidence to suggest that, in patients with PAH, treatment with oral treprostinil may be more cost effective than selexipag over a 6- to 12-month period.

Limitations {#Sec11}
-----------

ICD-9-CM and ICD-10-CM diagnosis codes, the standard method for identifying patients in claims studies, can be used to identify PH but are not specific to the subclassification of patients with PAH. These diagnosis codes used for billing and administrative purposes do not align with the WHO clinical classification scheme, which classifies PH into groups of conditions that share similar underlying etiologies and are used by PH specialists to diagnose and medically manage PH \[[@CR25], [@CR31]\]. Thus, for this study, PAH was identified using previously developed algorithms for identifying patients with PAH from claims databases \[[@CR25], [@CR31]\] by combining requirements for a PH diagnosis and a claim for a PAH-indicated medication (i.e., an oral prostacyclin). Using diagnosis and pharmacy claims can be imprecise, and some patients may have been misclassified. However, since prostacyclin therapies are only indicated for the treatment of PAH, and most healthcare payers/insurers require a confirmed PAH diagnosis prior to authorization, the combination of a diagnosis and a PAH-indicated prostacyclin medication is likely to reduce the probability of a patient without PAH being included in the study cohort.

The study was conducted in a US managed care population, and PAH is a rare disease, thus the sample size was relatively small, so caution needs to be used while generalizing these results to other PAH populations. Some of the outcomes reported in this study (e.g., inpatient hospitalizations) may be more appropriate for longer follow-up than the 6 months reported herein. However, when continuous enrollment for 12 months was evaluated, small sample sizes resulted because of PAH being a rare disease, the relatively small market share given the recency of oral prostacyclin product launches, health insurance plan changes, and deaths. Thus, a sensitivity analysis of outcomes at 12 months was evaluated when possible. Patients in the oral treprostinil cohort appeared slightly sicker at baseline, with higher HCRU. However, PAH disease severity cannot be ascertained using claims data, which do not include clinical information such as pulmonary pressure, FC, or 6-minute walk test results. Thus, PAH disease severity could not be directly controlled for in the adjusted analyses. While prescription claims were available, we were unable to determine whether medication was dispensed and taken as prescribed. While this could result in changes to the utilization and costs of care, assessment of prescription days of supply indicated that patients with PAH receiving oral prostacyclin therapies in the study had high medication adherence. Lastly, claims data do not contain information on dose changes. Thus, understanding of the actual doses taken by patients, including changes during dosing titration, is challenging in claims data.

Conclusions {#Sec12}
===========

This is the first real-world study to compare healthcare utilization and costs between patients treated with either oral treprostinil or selexipag. In this real-world setting, the demographic and clinical characteristics of patients receiving oral treprostinil and selexipag for the treatment of PAH did not differ appreciably. Adherence and persistence were similar, although the mean MPR was slightly higher for patients receiving oral treprostinil. Few differences were seen in nonpharmacy-related utilization and costs between the oral treprostinil and selexipag cohorts, but lower pharmacy costs for oral treprostinil resulted in significantly lower total healthcare costs than for patients receiving selexipag.

Although a sensitivity analysis was conducted to examine HCRU over a 12-month follow-up, it will be important to look at longer-term utilization and cost outcomes among patients initiating oral prostacyclins in a larger population and to explore differences in clinical outcomes and mortality.
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